ZBD(SH:603567) Zheng Quan Zhi Xing·2025-08-11 16:26Summary of Key Points Core Viewpoint - The company, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., is providing a guarantee of up to RMB 400 million for its wholly-owned subsidiary, Heilongjiang Zhenbaodao Medical Trading Co., Ltd., to support its bank financing needs [1][5]. Group 1: Guarantee Details - The total guarantee amount is RMB 400 million, with an actual guarantee balance of RMB 345 million [1]. - The guarantee is subject to approval at the company's second extraordinary general meeting in 2025 [2]. - The guarantee will be effective from the date of approval until the annual general meeting in 2025 [4]. Group 2: Financial Overview of the Subsidiary - The subsidiary, Heilongjiang Zhenbaodao Medical Trading Co., Ltd., has total assets of RMB 322.91 million as of the first quarter of 2024 and RMB 345.39 million for the audited year [4]. - The total liabilities are RMB 248.88 million for the first quarter of 2024 and RMB 273.83 million for the audited year [4]. - The net profit for the first quarter of 2024 is RMB 2.48 million, while the audited net profit for the year is RMB 25.83 million [4]. Group 3: Board's Opinion and Risk Assessment - The board believes that the guarantee is necessary and reasonable, as the subsidiary has sufficient capacity to repay its debts [5]. - The company has a total external guarantee amount of RMB 1.791 billion, which is 22.96% of the latest audited net assets [5]. - There are no overdue guarantees, and the company has not provided guarantees to controlling shareholders or related parties [5].